Human gene therapy. Clinical development
Journal Title
- Human gene therapy. Clinical development
ISSN
- E 2324-8645 | P 2324-8637 | 2324-8645 | 2324-8637
Publisher
- Mary Ann Liebert Inc.
- Mary Ann Liebert
Listed on(Coverage)
| JCR | 2015-2019 |
|---|---|
| SJR | 2014-2019 |
| CiteScore | 2014-2019 |
| SCIE | 2014-2021 |
| SCOPUS | 2017-2020 |
| MEDLINE | 2016-2019 |
| EMBASE | 2016-2020 |
Active
- Active
based on the information
- SCOPUS:2020-10
Country
- USA
Aime & Scopes
- Human Gene Therapy is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes in-depth coverage of DNA, RNA, and cell therapies by delivering the latest breakthroughs in research and technologies. Human Gene Therapy provides a central forum for scientific and clinical information, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases. The Journal is divided into three parts. Human Gene Therapy, the flagship, is published 12 times per year. HGT Methods, a bimonthly journal, focuses on the applications of gene therapy to product testing and development. HGT Clinical Development, a quarterly journal, serves as a venue for publishing data relevant to the regulatory review and commercial development of cell and gene therapy products. Complete coverage includes: /// Improvements in vector developments /// Delivery systems /// Cell therapy /// Small nucleic acid therapeutics, including RNAi /// Clinical trials and animal models /// Clinical protocols /// Pre-clinical animal and in vitro studies to assess the safety of gene and cell therapy products used to support clinical applications /// Clinical trials including those in which the results are confirmatory or negative /// Topical issues related to the commercial development of gene and cell therapy products